Combined Use of Different Vaccine Models for Covid-19 And The Side-Effect Profile: A Single-Center Experience

Year 2024, Volume: 6 Issue: 1, 58 - 63, 29.01.2024

Ali Avcı , Muhammet Özer , Mehmet Serkan Yurdakul , Hakan Ozer , İsmail Baloğlu

https://doi.org/10.46310/tjim.1343477

Abstract

Background Currently, the most effective method to combat the COVID-19 pandemic is vaccination. This study investigated whether the combined use of vaccines obtained by different methods affected the side-effect profile.
Methods This cross-sectional study evaluated 437 people (265 females, 172 males; mean age, 42.04±14.49 years) who applied to the emergency department due to side effects among 26,974 vaccinated people (13,460 females, 13,514 males). The complaints and outcomes of the patients who applied to the emergency department were recorded.
Results While the rate of admission to the emergency department due to post-vaccination side effects was 1.6% among all vaccinated participants, this rate was 3% in the mixed vaccination group. It was observed that hospitalization was required in only two patients due to side effects. When vaccination methods were compared, the frequency of admission to the emergency department due to side effects was higher in the patients in the group in which the mRNA vaccine was mixed with the booster shot. However, it was not statistically significant (p=0.113).
Conclusion Different vaccine methods did not change the side effect profile, so different vaccine combinations could be used together if necessary.

Keywords

Covid-19, vaccine, side-effect

References

• WHO announces COVID-19 outbreak a pandemic. Europe: World Health Organization, 2020 [cited 2020 Apr 18]. Available at: https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic. Accessed Feb 11, 2021.
• Shimabukuro T. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. doi: 10.15585/mmwr.mm7002e1.
• Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020 Mar 19;91(1):157-160. doi: 10.23750/abm.v91i1.9397.
• Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-4. doi: 10.15585/mmwr.mm6950e2.
• Centers for Disease Control and Prevention. What to expect at your appointment to get vaccinated for COVID-19| CDC. Vaccines. 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect.html. Accessed Feb 11, 2021.
• Aranda S. Ten Threats to Global Health in 2019. s.l.: World Health Organisation (WHO), 2019. Available at: https://www.who.int/news-room/spotlight/ten-threatsto-global-health-in-2019. Accessed Feb 11, 2021.
• Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, Wang L, Zhao G, Ding Y, Zhao Y, Yin W. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Jun;21(6):803-12. doi: 10.1016/S1473-3099(20)30987-7.
• Farsalinos K, Niaura R, Le Houezec J, Barbouni A, Tsatsakis A, Kouretas D, Vantarakis A, Poulas K. Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep. 2020 Apr 30;7:658-63. doi: 10.1016/j.toxrep.2020.04.012.
• Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko SI, Svistunov AA, Petrakis D, Spandidos DA, Aaseth J, Tsatsakis A, Tinkov AA. Zinc and respiratory tract infections: Perspectives for COVID‑19 (Review). Int J Mol Med. 2020 Jul;46(1):17-26. doi: 10.3892/ijmm.2020.4575.
• Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, Nitulescu G, Ion GND, Spandidos DA Nikolouzakis TK, Drakoulis N, Tsatsakis A. Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review). Int J Mol Med. 2020 Aug;46(2):467-88. doi: 10.3892/ijmm.2020.4608.
• Aslanlar DA, Aydemir Ö, Kunt M, Koç E, Koç M. SARS-CoV-2 VOC 202012/01(B.1.1.7) Variant: Is it more dangerous? Selcuk Med J. 2023;39(1):19-23. doi: 10.30733/std.2023.01606.
• Milken Institute’s COVID-19 Treatment and Vaccine Tracker. Available at: https://covid-19tracker.milkeninstitute.org/#vaccines_intro. Accessed April 19, 2021.
• Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, Mohamud R. Side effects and perceptions following COVID-19 vaccination in Jordan: A randomized, cross-sectional study ımplementing machine learning for predicting severity of side effects. Vaccines (Basel). 2021 May 26;9(6):556. doi: 10.3390/vaccines9060556.
• Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, Turner RJ. Efficacy and safety of COVID-19 vaccines: A systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel). 2021 May 6;9(5):467. doi: 10.3390/vaccines9050467.
• Tekinalp A, Ceneli O, Guzel ME, Başgün MB, Demircioğlu S. The Etiological role of Sars-Cov-2 on hematologic diseases. Selcuk Med J. 2022;38(1):40-4. doi: 10.30733/std.2022.01538.
• Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernán MA, Lipsitch M, Kohane I, Netzer D, Reis BY, Balicer RD. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021 Sep 16;385(12):1078-90. doi: 10.1056/NEJMoa2110475.